Zacks Investment Research | Feb 07, 2018 09:30PM ET
On Feb 7, shares of Haemonetics Corporation (NYSE:HAE) reached a new 52-week high of $70.89, closing the session marginally lower at $69.73. The stock hit the high following impressive third-quarter fiscal 2018 earnings results, the day before.
Haemonetics had a great run on the bourses in the past year. The stock has returned 86.5% compared with the S&P 500 index’s gain of 16.6%. The return is also higher than the broader industry 's rally of 17.2%.
Considering this, one may expect the Massachusetts-based blood management company to scale new highs in the upcoming quarters. Further, the company delivered average positive earnings surprise of 17.5% in the trailing four quarters. A positive growth rate of 12.4% for the next year also instills optimism.
Estimate revision trends for the current year look impressive. In the last two months, one estimate has moved north, with no movement in the opposite direction.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.